Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.
Lehmann-Che J, André F, Desmedt C, Mazouni C, Giacchetti S, Turpin E, Espié M, Plassa LF, Marty M, Bertheau P, Sotiriou C, Piccart M, Symmans WF, Pusztai L, de Thé H. Lehmann-Che J, et al. Among authors: desmedt c. Oncologist. 2010;15(3):246-52. doi: 10.1634/theoncologist.2009-0243. Epub 2010 Mar 12. Oncologist. 2010. PMID: 20228131 Free PMC article. Clinical Trial.
Genomic index of sensitivity to endocrine therapy for breast cancer.
Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T, Valero V, Booser DJ, Hortobagyi GN, Pusztai L. Symmans WF, et al. Among authors: desmedt c. J Clin Oncol. 2010 Sep 20;28(27):4111-9. doi: 10.1200/JCO.2010.28.4273. Epub 2010 Aug 9. J Clin Oncol. 2010. PMID: 20697068 Free PMC article.
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M; HER2/TOP2A Meta-analysis Study Group. Di Leo A, et al. Among authors: desmedt c. Lancet Oncol. 2011 Nov;12(12):1134-42. doi: 10.1016/S1470-2045(11)70231-5. Epub 2011 Sep 12. Lancet Oncol. 2011. PMID: 21917518 Free article.
TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.
Győrffy B, Bottai G, Lehmann-Che J, Kéri G, Orfi L, Iwamoto T, Desmedt C, Bianchini G, Turner NC, de Thè H, André F, Sotiriou C, Hortobagyi GN, Di Leo A, Pusztai L, Santarpia L. Győrffy B, et al. Among authors: desmedt c. Mol Oncol. 2014 May;8(3):508-19. doi: 10.1016/j.molonc.2013.12.018. Epub 2014 Jan 5. Mol Oncol. 2014. PMID: 24462521 Free PMC article.
237 results